However, in NSCLC, ALK positivity detected via IHC is commonly regarded as typical prompt of ALK‐TKI treatment, despite occasional instances of reported false positives and discordant results associated with ALK amplifications or activating mutations identified through FISH and NGS [8, 9]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.